Quadria Capital Closes US$1.07 Bln Fund To Drive Healthcare Investments In Asia
KUALA LUMPUR, May 27 (Bernama) -- Quadria Capital has announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original US$800 million target. (US$1=RM4.20)
The close comprises over US$954 million in primary commitments and US$114 million in co-investment capital, with an additional US$300 million expected during the investment period—bringing total potential deployment to around US$1.3 billion.
The oversubscribed fund cements Quadria’s position as the largest dedicated healthcare private equity fund in South and Southeast Asia, and marks a roughly 60 per cent increase over its previous US$600 million fund raised in 2020.
Quadria Capital Co-Founder and Managing Partner, Abrar Mir said with Asia expected to account for 40 per cent of global healthcare growth by 2030, this fund positions the firm to lead the sector’s transformation across the region.
“It reflects deep global investor conviction in the transformational opportunity in Asian healthcare, where social impact and financial performance go hand in hand,” he said in a statement.
Quadria’s investor base for Fund III spans continents, with support from leading sovereign wealth funds, global asset managers, and strategic corporates across North America, Europe, and the Gulf Cooperation Council (GCC)—particularly Saudi Arabia, the United Arab Emirates, and Bahrain.
New commitments also came from institutional investors in India, including banks, insurance firms, and family offices. The fund also saw strong re-ups from impact investors, highlighting continued confidence in Quadria’s dual mandate of financial return and social impact.
About 40 per cent of Fund III is already deployed, including investments in Aragen Life Sciences (a global CRDMO), NephroPlus (Asia’s largest dialysis chain), and Maxivision (India’s leading eye care chain). Two more deals in Southeast Asia are expected to close soon.
The fund will support approximately 10 companies through a mix of majority and minority stakes, augmented by co-investments from Limited Partners to drive further scale.
With a strong exit track record from Funds I and II, Quadria aims to continue delivering both financial returns and measurable social impact across Asia’s rapidly evolving healthcare landscape.
-- BERNAMA